Global Acute Myeloid Leukemia Treatment Market is expected to Witness a Growth Rate of 11.9% to Reach US$ 2,685.1 Mn Market Size by 2030. 

Industry drivers and trends:

High incidence and prevalence of acute myeloid leukemia is expected to support global acute myeloid leukemia treatment market growth over the forecast period. According to American Cancer Society (ASC), there were ~60,000 cases of leukemia were diagnosed in the U.S. in 2022, out of which 20,050 new cases of acute myeloid leukemia (AML) are expected.

Furthermore increasing research and development, and product launches is expected to further boost market growth over the forecast period. For instance, Moleculin Biotech, Inc., received approval from the Agenzia Italiana del Farmaco (AIFA, the Italian Medicines Agency competent authority) and the Istituto Superiore di Sanità (ISS, the Italian National Institute of Health) for its Phase 1/2 trial evaluating Annamycin in combination with Cytarabine (Ara-C) in the treatment of subjects with AML who are refractory to or relapsed after induction therapy (MB-106).

Newer therapies such as targeted therapy are being introduced in the market which is supporting global acute myeloid leukemia market growth. 

Key Takeaways:

• North America region occupies highest market share in the global acute myeloid leukemia market followed by Europe
• Chemotherapy segment is expected to hold majority of the market share over the forecast period in the therapy area segment
• Hospital pharmacies segment is expected to show highest growth over the forecast period owing to better access to patients, and availability
• Factors such as low competition in the space, and lack of robust therapies given the difficulty of treatment, and unmet needs in the space present lucrative opportunities for pharmaceutical organizations for research and development

Segments Covered in the Global Acute Myeloid Leukemia Treatment Market Report:

The global acute myeloid leukemia treatment market is segmented based on treatment type, distribution channel, region as follows:

• Treatment Type (Revenue, USD Million; 2022–2030)
  • Chemotherapy
  • Targeted Therapy
  • Others
• Distribution Channel (Revenue, USD Million; 2022–2030)
  • Hospital Pharmacies
  • Specialty Pharmacies
  • Online Pharmacies
• Region (Revenue, USD Million; 2022–2030)
  • North America 
    • U.S.
    • Canada
  • Europe 
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific 
    • China
    • Japan
    • South Korea
    • India
    • ASEAN
    • Rest of APAC
  • Latin America 
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East & Africa 
    • Saudi Arabia
    • UAE
    • Rest of MEA